Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Intra-Cellular Therapies Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ITCI
Nasdaq
2836
https://www.intracellulartherapies.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Intra-Cellular Therapies Inc
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
- May 8th, 2024 12:00 pm
Intra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...
- May 8th, 2024 7:13 am
Intra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA Sales
- May 7th, 2024 1:12 pm
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
- May 7th, 2024 12:40 pm
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
- May 7th, 2024 11:30 am
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
- May 1st, 2024 2:01 pm
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
- Apr 30th, 2024 12:00 pm
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
- Apr 25th, 2024 2:01 pm
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Apr 24th, 2024 8:01 pm
3 Biotech Stocks With Skyrocketing Potential: April 2024
- Apr 24th, 2024 3:36 pm
10 Best Performing Biotech ETFs in 2024
- Apr 22nd, 2024 3:10 pm
Intra-Cellular Therapies Prices Public Offering of Common Stock
- Apr 18th, 2024 12:46 am
Biotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy Point
- Apr 17th, 2024 1:44 pm
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
- Apr 17th, 2024 1:21 pm
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
- Apr 17th, 2024 11:36 am
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
- Apr 16th, 2024 8:06 pm
Intra-Cellular Launches 23% To Record High, Breaking Out After Depression Drug Scores Big
- Apr 16th, 2024 8:00 pm
Intra-Cellular builds case for depression drug with late-stage trial win
- Apr 16th, 2024 11:14 am
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
- Apr 16th, 2024 11:00 am
Intra-Cellular Therapies (NASDAQ:ITCI) advances 6.5% this week, taking five-year gains to 467%
- Mar 24th, 2024 2:31 pm
Scroll